Back to News
Market Impact: 0.25
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Source: globenewswire.com
Healthcare & Biotech
Safety findings presented at ASN Kidney Week 2026 remained favorable among 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning. The findings further support the RECLAIM-LN program; no efficacy results or additional safety figures were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Cigna raises annual profit forecast on strength in health services unit
- Truist raises Zimmer Biomet stock price target on robotics progress